This new FDA-approved shot is designed to break down the barriers that have kept too many people from accessing PrEP.

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

Medically reviewed by Renita White, MD Mouth and tongue lesions are often one of the first symptoms of human immunodeficiency ...